Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fenaux

Showing results (101-110 of 432) with videos related to

Pageof 44
Sort By:
European Journal of Haematology|December 11, 2012
Disclosure of myelodysplastic syndrome diagnosis: improving patients' understanding and experienceCaroline Besson, Sandrine Rannou, Hicham Elmaaroufi, et al.
Haematologica|April 5, 2011
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaRaphael Itzykson, Claude Gardin, Cécile Pautas, et al.
Blood|October 15, 2005
NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndromeThorsten Braun, Gabrielle Carvalho, Arnaud Coquelle, et al.
British Journal of Haematology|June 16, 2017
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacyPierre Fenaux, Petra Muus, Hagop Kantarjian, et al.
British Journal of Haematology|June 19, 2015
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)Erica Bello, Andrea Pellagatti, Jacqueline Shaw, et al.
European Journal of Haematology|May 16, 2015
Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patientsJérôme Stirnemann, Najett Kaddouri, Medhi Khellaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancerMarie-Cécile Le Deley, Florence Suzan, Bruno Cutuli, et al.
Blood|October 12, 2018
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopeniaMichael Dickinson, Honar Cherif, Pierre Fenaux, et al.
Case Reports in Hematology|April 2, 2020
Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old WomanClaire Cochet, Marion Simonet, Julie Cattin, et al.
Leukemia Research|May 20, 2014
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidineCecile Bally, Lionel Adès, Aline Renneville, et al.
Pageof 44

Showing results (101-110 of 432) with videos related to

Sort By:
Pageof 44
European Journal of Haematology|December 11, 2012
Disclosure of myelodysplastic syndrome diagnosis: improving patients' understanding and experienceCaroline Besson, Sandrine Rannou, Hicham Elmaaroufi, et al.
Haematologica|April 5, 2011
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaRaphael Itzykson, Claude Gardin, Cécile Pautas, et al.
Blood|October 15, 2005
NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndromeThorsten Braun, Gabrielle Carvalho, Arnaud Coquelle, et al.
British Journal of Haematology|June 16, 2017
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacyPierre Fenaux, Petra Muus, Hagop Kantarjian, et al.
British Journal of Haematology|June 19, 2015
CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)Erica Bello, Andrea Pellagatti, Jacqueline Shaw, et al.
European Journal of Haematology|May 16, 2015
Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patientsJérôme Stirnemann, Najett Kaddouri, Medhi Khellaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2006
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancerMarie-Cécile Le Deley, Florence Suzan, Bruno Cutuli, et al.
Blood|October 12, 2018
Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopeniaMichael Dickinson, Honar Cherif, Pierre Fenaux, et al.
Case Reports in Hematology|April 2, 2020
Arsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old WomanClaire Cochet, Marion Simonet, Julie Cattin, et al.
Leukemia Research|May 20, 2014
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidineCecile Bally, Lionel Adès, Aline Renneville, et al.
Pageof 44